To determine whether the anti‐tumor efficacy of nivolumab compared with that of docetaxel was consistent across various subgroups, the pooled efficacy in terms of PFS and OS was estimated within the various subgroup defined based on the following classification variables: PD‐L1 expression, ECOG status, histology, and study design (Table 3). The gene discussed is CD274; the disease is neoplasm.